The Center for Immuno-Oncology (CIO) investigates how our immune system reacts to cancer and what we can do to improve tumour immunity. We combine deep fundmental understanding of immunology with preclinical studies to translate new knowledge into clinical trials with the aim of developing new life-saving treatments for a spectrum of cancers.
Oxford’s long history of excellence in immunology is now focused on cancer, and CIO is the hub of the University-wide Oxford Cancer Immuno-Oncology Network (OCION) which links immuno-oncology researchers from multiple disciplines from across the University of Oxford, its affiliated hospitals and industrial partners.
CIO News
£1.7 million for vaccine to prevent lung cancer
2 April 2024
Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.
What's new for Oxford Cancer
-
Research in Focus for Childhood Cancer Awareness Month
18 September 2024
-
CRUK funding success to take LynchVax from an OCION Pump Prime award towards a clinical trial
16 September 2024
-
CRUK Oxford Development Fund - now open for applications!
16 September 2024
-
OxCODE travel award winner featured by Cancer Research UK
13 September 2024
-
Oxford and NTU Singapore Study discovers new process for cells to repair DNA damage
11 September 2024